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1. Introduction 
Due to its highly contagious nature, the control of tuberculosis (TB) is strongly dependent 
on the efficiency of diagnosis. Natural history of TB comprises two main stages: a latent, 
non-infective form, in which bacilli are efficiently controlled by the human defense system 
and, active TB disease, whose pulmonary form is the most common and infective variant 
in humans (Figure 1). Diagnosis of TB is needed at different stages: the detection of latent 
TB, a condition estimated to be present in one third of the world population (Russell et al 
2010), screening tests for active TB in large populations and confirmatory/drug-
susceptibility diagnostic tools aimed to select appropriate chemotherapy regimes. In 
particular, tools to screen active, contagious TB cases are critical to overcome diagnosis 
delays, transmission and spread of the disease, and represent one of the top priorities for 
TB control. For more than a century, diagnosis of active TB has been essentially based on 
sputum smear microscopy (SSM). Simple and rapid, considered a low-cost control tool, 
SSM fails however to detect about half of active pulmonary cases since its sensitivity is 
compromised by low bacterial loads: only above 104 bacilli per ml of sputum are 
detectable by SSM (Abebe et al, 2007). Moreover, detection of positive smears needs to be 
confirmed in three independent samples so that mycobacteria other than M. tuberculosis, 
which may be present as normal flora do not generate false positive diagnosis results. 
When suspected cases still remain, time-consuming and high-cost M. tuberculosis cultures 
are required. For many decades, a myriad of alternative tools have been explored to 
replace SSM for screening active TB. After growth of the pathogen inside a body, 
exposition to bacterial components is followed by the secretion of specific antibodies. 
Antibodies associated to active TB are not correlated to protective immunity, but their 
presence may be exploited as biomarker for active TB. In this chapter, the potential of 
antigen-antibody measurements to screen active TB will be pointed up, with a special 
emphasis in the need for controlling particular but large populations. The basis, 
challenges and opportunities of immune diagnosis will be described, putting an emphasis 
on our work involving novel technologies. 
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Fig. 1. Natural history of Mycobacterium tuberculosis infection. M. tuberculosis is an obligate 
pathogen normally acquired through respiratory tract. After infection, establishment of 
human response is able to contain microbial growth in 90 – 95% cases; this process is 
characterized by activation, recruitment and/or proliferation of distinct cells in the 
infectious foci, growth control and confinement of the pathogen inside a granuloma, a 
condition called as latent TB (Inlet a). In contrast, immune compromised-associated 
conditions lead to active disease, characterized by microbial growth, tissue damage and 
antibody production (Inlet b). Case finding of active cases is critical to stop TB transmission. 
Antibodies, depicted using the symbol Y, and antigens liberated from bacteria may serve as 
biomarkers at this infection stage. 
2. The need of rapid tests for diagnosing active TB 
Efficient treatment is available for most cases of TB. However, thousands of deaths are 
reported every day due to TB. Due to the fact that healthy immune systems are a condition 
for TB containment, malnourishment, poverty and a fail in Public Health coverage have 
been strongly associated to the development of active TB cases. The burdens of TB 
morbidity and mortality have a tremendous impact in young adults, children and women, 
and result in the loss of potentially healthy and productive life. It is estimated that active TB 
cases result in a strong economical impact through loss of work, absence from school and 
public health expenses. Accentuating this scenario, TB active cases also represent the major 
cause of death during human immunodeficiency virus (HIV) infection. To deal with this 
problem, the availability of simple diagnostic tools for the detection of tuberculosis is 
essential, as it is the basis to treat and control infective cases. During the last years, a set of 
novel diagnostic methodologies have been developed. Some popular examples are tools 
based on nucleic acid amplification, such as the polymerase chain reaction (PCR), or the 
introduction of radioactive probes to speed bacterial culture detection (WHO, 2009). Many 
new diagnostic technologies had been based on sophisticated equipment and highly 
specialized training, but up to 90% TB cases occur in low-income settings (WHO 2006), 
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making those methods unaffordable. Thus, novel approaches must be focused in the 
diagnosis of TB at high-burden settings. A few years ago, the World Health Organization 
(WHO) has prompted for the development of tests for active TB optimally fulfilling seven 
requirements, the so-called ASSURED diagnostic tests: 
 Affordable by those at risk of infection 
 Sensitive (few false-negatives) 
 Specific (few false-positives) 
 User-friendly (simple to perform and requiring minimal training) 
 Rapid (to enable treatment at first visit and Robust (does not require refrigerated 
storage) 
 Equipment-free 
 Delivered to those who need them 
Currently, the development of ASSURED tests has been considered for the control of a 
variety of diseases, including TB, malaria, syphilis and dengue. Considering the number of 
affected people and the feasibility for its development, the availability of an ASSURED test 
for the screening of active TB would have a tremendous, positive impact in World Public 
Health (Mabey et al, 2004). Before the emergence of human immune deficiency virus (HIV) 
epidemy, TB became “invisible to international donors and taken to be a fact of life in the 
most-affected parts of the world” (Dye & Williams, 2010). Thereby, the search for better 
vaccines, therapeutic and diagnostic tools was neglected for decades, even for more than a 
century in some cases (Kaufmann & Parida 2007). At present, this lack of technological 
developments has made TB control tools virtually inaccessible for most endemic settings. 
Manipulation of M. tuberculosis specimens represents a high level biological risk, requiring 
high-cost, sophisticated facilities. For these reasons, diagnosis based on the immune 
response to M. tuberculosis represents an alternative to cover the main indications for an 
ASSURED test, including minimal handling requirements, rapidity and adaptability to 
close-to- the-patient formats. In this chapter we will describe the biological basis, challenges 
and opportunities related to immunological tests, with an emphasis on point-of-care (POC) 
tests. In addition to rapid immunochromatography formats that have been explored by 
various groups, we herein propose the development of friendly, label-free platforms, using 
Micro-Electro-Mechanical Systems (MEMS). 
3. Human immune response to Mycobacterium tuberculosis infection 
It is estimated that one third of the World population is currently infected by M. tuberculosis 
(Dye & Williams, 2010). After infection, M. tuberculosis is promptly recognized by the innate 
immune system. Pattern-recognition receptors located at the surface of myeloid cells, such 
as mannose recognizing receptors located in macrophages or dendritic cells, recognize 
molecular patterns commonly associated to pathogens and immediately respond through 
pro-inflammatory signals (Dorhoi et al, 2011). Whether this process is able to control the 
spread of the bacilli is still controversial. Supporting the hypothesis is the fact that a number 
of healthy contacts have been reported with no apparent sign of acquired immunity, thus 
suggesting that innate mediators were able to stop the infection before the establishment of 
adaptive, memory-derived responses (Dorhoi et al, 2011). In most people, however, the 
establishment of innate immunity allows a set of specific defence mechanisms to be 
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initiated. This process involves destruction of bacilli by professional phagocytes, and 
presentation of pathogen molecular fragments (antigens) to lymphocytes, followed by 
activation and proliferative steps. This response, also known as adaptive immunity, may 
give rise to either protection via the containment of the bacilli inside a granuloma, or an 
exacerbated inflammatory process associated to destructive pathology. In both cases, 
lymphocytes that specifically recognize their cognate antigen are activated, leading to the 
production of cytokines or antibodies, the destruction of infected cells and, the formation of 
memory lymphocyte clones. Since these processes involve mechanisms specifically 
originated during M. tuberculosis infection, the associated biomarkers have been largely 
exploited for diagnostic purposes. 
An overview of adaptive, cell-mediated responses to M. tuberculosis is schematized in Fig. 2. 
Adaptive responses take place when lymphocytes recognize mycobacterial molecules as  
 
Fig. 2. Cell-mediated immunity against M. tuberculosis infection. After recognition and 
engulfment of the pathogen by phagocytic cells (macrophages, dendritic cells), bacterial 
components (antigens) are processed into small fragments and presented to lymphocytes. 
Thymus-derived T-lymphocytes recognize antigens presented by antigen-presenting cells, 
such as macrophages, dendritic cells and B-lymphocytes. After antigen recognition, T-cells 
are activated and develop into cytokine-producing (CD4+) cells or cytolytic (CD8+) 
mediators. B-cells are directly activated by antigens. However, fully activation of B-cells 
may be coordinated by interactions with CD4+ T-cells, in the case of peptide antigens, or 
through thymus-independent, poorly described pathways for non-protein antigens, such as 
lipids. Figure is out of scale. 
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foreign entities (as antigens). Two lymphocyte families, the T and B-cells, are activated after 
encountering with their matching antigen, then develop into the effectors of adaptive 
immunity. For T cells, presentation of foreign entities by antigen-presenting cells is 
mandatory for recognition. In contrast, B cells recognize their cognate antigens through 
direct interaction via the B-cell receptor. Once activated, B and T cells trigger a variety of 
functions, mainly including: (a) secretion of cytokines and chemoattractants by CD4+ helper 
T-cells, (b) lysis of infected cells via the release of lytic enzymes by CD8+ cytotoxic T-cells, 
(c) secretion of antibodies by plasma B-cells that have been derived from activated B-
lymphocytes, (d) production of a number of long-lived memory T- and B-cells, which last 
for many years circulating in the bloodstream and monitor for  infection (either newly 
developed or endogenously re-activated). 
As depicted in Figure 2, some responses related to cell-mediated immunity are restricted to 
active infection. One illustrative example is the release of some pro-inflammatory cytokines 
by T-cells, such as interferon-gamma. The secretion of specific antibodies by plasma B-
lymphocytes also occurs during active or newly acquired TB, where antigen-presenting cells 
are charged with bacterial moieties. Some of the immune responses during active infection 
are known to be critical for arresting the growth of M. tuberculosis. In contrast, antibody 
secretion has been considered irrelevant, although some recent studies suggest a role for 
antibodies on the fate of M. tuberculosis infection (Glatman-Freedman et al, 2010). Yet, 
secretion of antibodies during bacterial growth (i.e. during active infection) can be exploited 
to detect infectious cases, thus contributing to stop TB transmission.  
Isolated specific antigens have been used for detecting antibodies in human plasma, through 
the measurement of antigen-antibody reactions in vitro. Alternatively, antibodies may be 
produced in the lab and used to capture mycobacterial antigens that have been secreted to 
body fluids. Because free mycobacterial antigens are not encountered in many biological 
fluids, our work has been dedicated to the detection of antibodies. Importantly, antibodies 
associated to M. tuberculosis disease are found in sera from individuals affected by both 
pulmonary and extra-pulmonary TB, thus allowing the detection of difficult-to-detect TB 
pathologies (Daniel, 1989). Challenges related to the production of antigens for diagnostic 
tests will be presented in the following sections. 
4. Antigen repertoire of M. tuberculosis 
Specific activation of immune cells against M. tuberculosis occurs after the recognition of 
bacterial components as foreign entities. With about 4,000 genes (TubercuList web page), M. 
tuberculosis synthesizes a complex array of molecular products, mainly composed of 
proteins, lipids and carbohydrates. Box 1 summarizes the highlights of different antigens 
from the bacillus. 
5. Immunodiagnosis of TB: From Koch to POC tests 
A few years after Robert Koch discovered M. tuberculosis, his work was largely dedicated to 
look for a cure against TB disease, which was the major health threat in Europe by the time. 
His work allowed the description of M. tuberculosis extracts, obtained by glycerol extraction 
of liquid cultures of the bacilli (Kaufmann & Schaible 2005). Although this material, called 
tuberculin, was found unable to inhibit the growth of M. tuberculosis in guinea pigs or 
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Box 1. Antigens from Mycobacterium tuberculosis 
humans, Koch reported for the first time that previously-infected individuals developed a 
local inflammation at the site where tuberculin was injected, whereas healthy controls did 
not present such a response (Kaufmann & Schaible 2005). This hypersensitivity reaction was 
later related to the activation of memory T-cells, which are able to recognize tuberculin-
containing antigens. Named the delayed-type hypersensitivity (DTH) test, the intradermal 
reaction to tuberculin constituted the first diagnostic tool based on the immune response 
against M. tuberculosis, and has been used for more than a century to diagnose latent TB 
(WHO 2006). During latent TB, memory T-lymphocytes may be searched through either 
DTH tests performed in-vivo, or more rapid, in-vitro cytokine analyses (Lalvani 2007, 
Hanekom et al, 2004). In any case, crude mixtures of mycobacterial antigens, such as 
tuberculin, often produce unspecific, false-positive results. In fact, M. tuberculosis shares a 
number of antigens with other microorganisms, including vaccine strains against TB. To 
circumvent this problem, the use of single or a small cocktail of antigens has been proposed. 
Two secreted protein antigens, ESAT-6 and CFP-10, are worth of mention since a high 
specificity and abundant T-cell responses have been associated to them (Fox et al, 2007). 
More recently, a non-protein, lipid antigen has also been proposed as a reagent to look for 
DTH responses (Komori et al 2011). Considering the lack of gene polymorphism of lipid-
presenting molecules in humans (De Libero & Mori 2010), introduction of lipid antigens for 
diagnosing latent TB appears very promising. 
In contrast to memory T-cell responses, production of antibodies requires the presence of 
plasma circulating B-lymphocytes, a phenomenon associated to active infection (see Figure 
2). Therefore, the search for antigen-antibody reactions has been largely explored to 
diagnose active TB. Such a reaction may be measured in a wide set of platforms, from old 
M. tuberculosis is a bacterial pathogen of atypical molecular composition: 
 Protein molecular patterns include stress-inducible proteins of wide distribution 
within bacteria, enzymes presenting homology with many other human pathogens 
(bacteria and parasites), and newly described or putative gene products devoid of 
homology vis-à-vis any other peptide annotated so far (16% of M. tuberculosis open 
reading frames are novel sequences). 
 Cellular wall is unusually thick, conferring unique properties of tinction (M. 
tuberculosis is not Gram+ nor Gram-) and atypical antibiotic susceptibility patterns. 
 Genes related to lipid metabolism are especially abundant (5-fold more genes in M. 
tuberculosis genome compared to that of Escherichia coli). In accordance, the Koch 
bacillus produces lipids with amazing structural features and sizes (fatty acids up to 80 
carbons length). Many of these lipids are recognized as antigens during active TB. 
 Carbohydrate products have distinctive structures. Polysaccharides and glycoconjugates 
(glycolipids, glycoproteins) comprise molecular motifs recognized by innate immune 
cells and important virulence factors. In contrast to findings in model animals, sera from 
M. tuberculosis-infected humans strongly recognize sugar structures. 
 Shared with other bacteria, some small phosphorus-containing compounds, 
phosphoantigens, constitute a separate group of antigens in M. tuberculosis. 
Phosphoantigens activate a set of unusual T-cells and possess interesting therapeutic 
effects against specific lymphomas. 
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agglutination and electrophoretic immune precipitation techniques (Zykov et al 1966), to 
lab-on-chip formats, in which a set of laboratory procedures are automatically performed 
within a microfluidics technology-based chip (Schulte et al 2002). Contrasting to cell-
mediated responses, the assessment of antigen-antibody reactions does not require special 
conditions, such as regulated temperature or specific environment. In addition, no 
exposition to high level biological risk bacilli is involved to obtain plasma or serum samples.  
The search for antibodies in body fluids may be performed using a variety of technological 
platforms. Currently, Enzyme-Linked ImmunoSorbent Assay (ELISA) is the most common 
method for analyzing antigen-antibody reactions. The typical format used for screening 
antibodies in sera, an indirect ELISA, is schematized in Figure 3. ELISA has been widely 
used since the late 80's to screen for active TB (Daniel, 1989). Crude bacterial extracts, 
including tuberculin, represented the first bacterial materials explored as reagents. One of 
the most popular mixtures was Antigen-5, a preparation composed of various proteins and 
lipoarabinomannan, a specific cell-wall glycolipid (Daniel, T. M. et al, 1985). As modern 
Biochemistry tools have been developed, more purified, specific antigens have been 
obtained. Up to now, many proteins, post-translationally modified peptides, glycolipids and 
saccharides have been proposed as antigens for immunodiagnosis of active TB (Steingart et 
al, 2009). 
  
Fig. 3. The Enzyme-Linked ImmunoSorbent Assay for the detection of antibodies. A selected 
antigen is used to coat a plate surface (1); a solution of non-reacting protein, such as bovine 
serum albumin, is used to block non-occupied sites at the plate surface, avoiding non-
specific binding between serum proteins and the plate (2); serum is added and antibodies 
bind to matching epitopes of immobilized antigens (3); non-reactive antibodies from sera are 
eliminated by washings (4); a secondary antibody linked to an enzyme is used to bind the 
primary, tuberculosis-associated antibody (5); the substrate of the enzyme is added allowing 
to enzyme-dependent colorimetric changes, which are quantified through 
spectrophotometry (6). 
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The development of ELISA represented a breakthrough for the detection of antigen-
antibody responses. Before enzyme-linked tests, cumbersome and/or hazardous methods, 
including radioimmunoassays (RIA), importantly limited the application of immune 
diagnostic tests for large populations (Lequin, 2005). Yet, an ELISA presents important 
limitations for large-scale applications. Major drawbacks associated to this technique 
include: the need of large amounts of samples, a multistep procedure poorly suitable for 
high throughput scales, and high costs related to the use of enzymatic markers, specialized 
equipment and trained personnel. Recently, the development of more friendly, equipment-
free technologies has been largely explored, importantly including the search for 
miniaturized analytical devices. In particular, the integration of currently existing detection 
methods, such as those based on antigen-antibody responses, into microdevices represents a 
promise for bringing diagnostics closer to those who need it. The introduction of 
microtechnologies may afford automated systems for the detection of TB at the site of 
patient care. Such devices have been called Point-Of-Care (POC) tests. 
6. Current challenges for the development of POC tests for TB diagnosis 
TB is considered one of the most complex diseases ever established in humankind. Active 
TB has been related to multiple processes but not to any single pathogenic or host factor. 
Therefore, the demand of technological innovations for the development of POC tests is 
accompanied by a particular challenge regarding the selection of bioreagents. In the 
following paragraphs, we enumerate the major current limitations and possible 
technological solutions for the development of POC tests to diagnose active TB. 
6.1 The heterogeneous human response to M. tuberculosis antigens 
Up to now, few systematic studies to address the antibody response during tuberculosis in 
humans have been performed. The presence of different antibody secretion patterns in 
humans has been largely observed. HLA genes encoding for molecules presenting protein 
antigens, namely the Major Histocompatibility Complex (MHC) molecules, are known to be 
highly polymorphic in humans, and some data indicate this gene polymorphism as a source 
of variability to recognize peptide motifs by immune cells (Bothamley et al, 1989). On 
another side, the spectrum of responses at different stage of the disease may account for 
important variability. In this way, protein antigens that had proved high sensitivities in 
some trials, have given unsatisfactory results when tested in a different setting (Gennaro, 
2000). The use of species-specific antigens, not present in mycobacteria other than M. 
tuberculosis, is known to be required to avoid false-positive results, and antigens synthesized 
by vaccine strains are also precluded. According to a meta-analysis reported by Steingart et 
al. (2009), antibody detection methods could achieve high efficiencies only if a mixture of 
multiple antigens is used. Most analyzed trials failed, however, to include appropriate 
healthy controls, thus limiting the results in regard to test specificity. Therefore, in spite of 
the need to perform better diagnostic trials including appropriate controls, a conclusive 
remark is the convenience to use a cocktail of antigens. With this in mind, antibodies 
associated to active TB seem largely elicited by unusual, difficult to obtain mycobacterial 
antigens.  
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6.2 The structural nature of various sensitive, specific antigens is not addressable via 
recombinant technology 
According to serodiagnostic analyses performed in TB endemic settings (including ours), 
antigens able to achieve high diagnostics performances represent mycobacterial components 
non-addressable by genetic engineering. Some of the highest specificities and sensitivities 
have been found using glycolipids. These are fatty acyl-containing carbohydrate, secondary 
genetic products, whose biosynthesis involves multiple enzymatic steps, some of them still 
undefined. Lipoarabinomannan (LAM), di-O-acyl trehalose (DAT) and cord factor (CF) 
belong to this group of difficult-to-obtain highly performance antigens (Barihuta et al, 1993; 
Escamilla et al, 1996; López-Marín et al, 2003; Maekura et al, 1993; Julián et al, 2001; 
Simonney et al, 1996). Besides, some of the best protein antigens to diagnose active TB are 
post-translationally modified products, namely glycosylated proteins such as the 38-kDa, 
antigen (Espitia et al, 1989). Worth noting, the best diagnostic performances obtained with 
this protein have been found when it has been obtained from glycosylating mycobacterial 
cells. In contrast, a non-glycosylated 38-kDa antigen obtained by recombinant technology in 
Escherichia coli has shown poor efficiencies (Gennaro, 2000). 
6.2.1 Surrogate microbial sources of secondary-genetic products 
The isolation of glycosylated antigens involves cumbersome steps, making difficult their use 
in large-scale applications. The involvement of complex, methyl-containing fatty acyl 
structures in antibody recognition may limit the use of synthetic approaches for these 
antigens. In view of the structural similarity of glycolipids from M. tuberculosis and some 
other mycobacterial species, we looked for surrogate sources of glycolipids as antigens for 
TB diagnosis. Structural and serologic studies of glycosylated lipids from mycobacteria 
allowed the identification of Mycobacterium fortuitum, a species of rapidly growing non-
tuberculous mycobacteria, as surrogate source for two promising antigens: di-O-acyl 
trehalose (DAT) (Escamilla et al, 1996), and cord factor (López-Marín et al, 2003). 
Interestingly, M. fortuitum synthesizes abundant quantities of DAT and cord factor. The 
antigens afford specific reactivities vis-à-vis healthy controls and patients infected with 
other pathogenic actinomycetes (López-Marín et al, 2003). In addition, glycolipids from M. 
fortuitum are not longer recognized by individuals with healed TB and do not present cross-
reactivities with vaccinated healthy controls (Escamilla et al, 1996). 
6.2.2 Peptide mimicry and combinatorial strategies  
Glycosylation has been detected as a critical factor for antibody recognition during active 
TB. For instance, the ability of antigens from M. tuberculosis to bind antibodies in sera from 
infected people is strongly decreased after periodate treatments, indicating that antibodies 
predominantly react with carbohydrate determinants (Udaykumar & Saxena, 1991). Sugar 
antigens in M. tuberculosis comprise protein and lipid glycoconjugates. At present, 
recombinant production of mycobacterial sugars is unfeasible, since biosynthetic pathways 
are still poorly described. A few decades ago, phage-display based technologies emerged as 
a powerful method to look for structurally diverse unknown ligands. Through recombinant 
technology, E. coli phages are modified to obtain combinatorial peptides libraries displayed 
on the virion surface (Smith, 1985). Through this technology, phage displayed peptides with 
affinity to any ligand can be identified by in-vitro screening (Figure 4). Using a phage 
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displayed dodecapeptide library, we have selected phages with specific binding to a serum 
directed towards M. tuberculosis carbohydrate antigens (Gevorkian et al, 2005). This 
approach resulted in the identification of peptides that mimic mannose-containing 
molecules of M. tuberculosis. A set of peptides were readily recognized by antibodies raised 
against mycobacterial sugars. More surprisingly, one of these peptides induced, in rabbits, 
the production of antibodies recognizing mannan. More recently, Bua and coworkers used 
this technology to obtain phages as useful reagents for the serodiagnosis of tuberculosis 
(Bua et al, 2009). 
 
Fig. 4. Phage Display technology for the identification of biological reagents. Combinatorial 
peptide libraries displayed in virion surfaces can be obtained through genetic engineering. 
These libraries have proved to be useful for the identification of antibody ligands, even for 
those associated to poorly defined antigens. In this method, antigens are immobilized on a 
plate (1) and incubated in the presence of phage suspension (2); non bound phages are 
removed by washings (3), and selected phage clones are obtained through pH-mediated 
elution (4); finally, selected clones are amplified (5). The selection cycle is usually repeated  
3 times. 
Oligopeptides have been found to mimic a set of 3D structures, including sugars, linear and 
conformational peptide epitopes. Therefore, phage display represents a promising 
technology for the identification of peptides able to replace difficult-to-obtain or previously 
unknown antigens. At present, our work is focused to find optimal conditions in order to 
use peptide mimotopes as immunodiagnostic reagents. 
6.2.3 New vectors for the recombinant production of post-translational modified 
antigens 
A different approach to get reagents for diagnosis of TB has been the production of 
glycosylated proteins of M. tuberculosis in novel expression systems. Traditionally, 
recombinant mycobacterial proteins have been produced in E. coli. Mycobacterial glycosyl 
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structures are distinct from mammalian carbohydrates. Thus, expression of M. tuberculosis 
glycoproteins in other actinomycetes, such as rapidly growing Mycobacterium smegmatis 
(Garbe et al, 1993) and Streptomyces (Lara et al, 2003) appears as an interesting tool towards 
the application of serodiagnostics.  
6.3 Currently available platforms for POC immunodiagnostics 
Screening tests to detect TB are essential to overcome the epidemic. In particular POC tests 
may be implemented at lower levels of health services, contributing to stop TB transmission. 
The use of microfluidic technologies seem of special interest since they are associated to 
small volumes of samples. For instance, POC tests have been already developed to monitor 
biomarkers in a few blood drops. Two platforms for the study of antigen-antibody 
interactions are described below, immunochromatography tests and microchip-based 
devices. 
6.3.1 Lateral-flow immunochromatography tests 
One of the most advantageous platforms for the study of antigen-antibody reactions is 
lateral-flow immunochromatography. The basis of this method is schematized in Figure 5. 
Immunochromatography tests enable added value to antigen-antibody reactions since they 
allow higher throughput, reduced volume of samples, as well as lower costs than traditional 
immunoassays, since no specialized equipment or skilled personnel are necessary. Although 
this format has been used in many endemic settings, antigen evaluations vis-à-vis healthy 
controls or related pathologies require further studies. To our knowledge, highly specific 
glycolipid antigens, hydrophobic in nature, have not been included in 
immunochromatography formats.  
6.3.2 Micro-Electro-Mechanical Systems (MEMS) 
Based on resistant but flexible silicon platforms constructed through microchip-based 
technologies, MicroElectroMechanical Systems (MEMS) are micrometric devices which 
include mechanical parts, such as actuators, sensors or integrated microfluidic systems. 
MEMS have been widely used in aerospace and automotive industry. Examples of some 
popular MEMS are microaccelerometers in crash air-bag systems or micromirrors for 
projection systems. Some of the most attractive features in MEMS are reliability and low-
cost, which are associated to their large batch processing. Interestingly, a MEMS is able to 
perform automated analyses, including transport, separations, chemical reactions and 
sensing. All necessary instruments can be integrated in a single device, the MEMS, so that 
new terms, micro Total Analysis Systems (μTAS), and “Lab-On-a-Chip” (LOC) technologies 
have been coined for such instruments. Over the course of the past fifteen years, MEMS 
have also been explored for a set of biomedical applications, including metabolite analyses, 
drug testing, drug discovery, combinatorial assays for DNA screening and, obviously, 
immunodiagnosis (Hedlund, 2009). Figure 6 shows a scanning electron micrography of a 
MEMS. A detailed description of MEMS is out of the scope of this chapter. However, we 
enumerate the key features allowing this technology to be a promising tool for the 
development of ASSURED tests for diagnosis (Box 2).  
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Fig. 5. Immunochromatography platform for assessment of antigen-antibody reactions. 
Immunochromatography strips contain a sample pad, in which biological fluids are 
deposited. Capillarity induces a lateral flow of the sample throughout the pad. Frequently, 
nanocolloidal gold particles are functionalized for conjugation to total antibodies. Antigen 
immobilized as a line in the nitrocellulose strip captures the antibody-colloidal gold 
complex. A control line reacting with colloidal gold is also present. After developing, the 
test can be read since purple lines develop if colloidal gold is hold.  
To illustrate the suitability of MEMS technology for clinical POC tests, a good example is the 
possibility to sense biological markers in a sample using label-free technologies. In MEMS, 
physical properties, such as conductivity or mass changes, are usually analyzed through 
electric or optical low-cost systems (Battiston et al, 2001; Fischer, 2011). For immune 
diagnostic systems, the capture of antibodies by antigen-displaying surfaces will result in 
changes of mass or conductivity parameters, both of them addressable through MEMS 
standard technologies (Figure 7).  
 
Fig. 6. Panoramic image (a) and scanning electron micrographs (b, c) of a 
MicroElectroMechanical System (MEMS). Constructed using microchip technology, such as 
lithography on silica supports, MEMS also contain mechanical components, including 
beams, gears, diaphragms, grooves, orifices, springs or suspensions and optical systems. 
Three dimensional fabrication processes allow the design of automated systems able to 
reproduce any laboratory procedure. 
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Box 2. MicroElectroMechanical Systems (MEMS) at a glance 
 
Fig. 7. Label-free measurement systems in MEMS include cantilevers. If antigens are 
immobilized onto a quartz crystal, fine mass changes, as those produced by antibody 
capture, will result in measurable alterations in the quartz resonance frequency, an optical 
property that can be precisely detected combining the use of a laser microbeam and a 
photodetector 
7. Conclusion 
A rapid and affordable test for detecting contagious TB patients is the cornerstone of current 
strategies for TB control. Although a set of clever methods has been proposed for this 
objective, the search for new tools adaptable to low-resource endemic settings is still a 
demand. The search of antigen-antibody responses for diagnosing active TB represents a 
promising alternative, since the associated methods may fulfill the major diagnostic 
requirements, namely minimal handling, rapidity and adaptability to point-of-care formats. 
Future success of immunodiagnosis tools for detecting TB will depend on both basic and 
technological advances: (1) The identification of specific, affordable biological reagents for 
large scale production (antigens, antibodies or fragments) and (2) The development of 
immunological tests into low-cost, friendly formats. According to different studies 
 MEMS are machines with sizes ranging from a micrometer to a few milimetres 
 Including mechanical and optical parts, such as actuators, motors or sensors, MEMS 
are automated Lab-On-Chip machines 
 Batch processing determines very low-costs for an individual machine. 
 A variety of materials in MEMS technology, including some new advanced materials 
make possible the application of MEMS in Biomedicine 
 Metal surfaces able to immobilize a set of molecules, by keeping bioactivity 
 Some developments for biomedical applications already follow clinical tests for their 
introduction to the market. These include bioMEMS to sense glucose during diabetes 
or antibodies levels to detect dengue  
www.intechopen.com
 
Understanding Tuberculosis – Global Experiences and Innovative Approaches to the Diagnosis 
 
392 
addressing antigen-antibody responses in different populations, the search for antibodies in 
TB patients must include specific peptides, but also non-protein (lipid) and post-
translational modified antigens, such as glycosylated proteins. In this regard, strategies to 
obtain complex antigens are critical. The development of novel expression systems and 
phage-display technologies could be the answer. Finally, we herein suggest that, in addition 
to further improvements of the already explored immunochromatography strips for TB 
diagnosis, Micro-ElectroMechanical Systems (MEMS) deserve a particular attention to 
develop better POC tests for diagnosing active, but also to look for tests addressing the 
detection of inactive, latent TB. 
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